D-Glutamic Acid

Overview

DrugBank ID
DB02517
Type
Small Molecule
US Approved
NO
Other Approved
NO
Clinical Trials
Phase 0
0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Identification

Generic Name
D-Glutamic Acid
DrugBank Accession Number
DB02517
Background

Glutamic acid is the most common excitatory neurotransmitter in the central nervous system.

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 147.1293
Monoisotopic: 147.053157781
Chemical Formula
C5H9NO4
Synonyms
Not Available

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UThermolysinNot AvailableGeobacillus stearothermophilus
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as glutamic acid and derivatives. These are compounds containing glutamic acid or a derivative thereof resulting from reaction of glutamic acid at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Glutamic acid and derivatives
Alternative Parents
D-alpha-amino acids / Amino fatty acids / Dicarboxylic acids and derivatives / Amino acids / Carboxylic acids / Organopnictogen compounds / Organic oxides / Monoalkylamines / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Aliphatic acyclic compound / Alpha-amino acid / Amine / Amino acid / Amino fatty acid / Carbonyl group / Carboxylic acid / D-alpha-amino acid / Dicarboxylic acid or derivatives / Fatty acid
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
D-alpha-amino acid, glutamic acid (CHEBI:15966) / Other amino acids (C00217)
Affected organisms
Not Available

Chemical Identifiers

UNII
Q479989WEA
CAS number
6893-26-1
InChI Key
WHUUTDBJXJRKMK-GSVOUGTGSA-N
InChI
InChI=1S/C5H9NO4/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H,7,8)(H,9,10)/t3-/m1/s1
IUPAC Name
(2R)-2-aminopentanedioic acid
SMILES
N[C@H](CCC(O)=O)C(O)=O

References

Synthesis Reference

Toshiyuki Hamaoka, Kayoko Tateishi, "Producing highly specific, low cross-reactive antibody by immunizing with copolymer of D-glutamic acid and lysine." U.S. Patent US4722899, issued June, 1985.

US4722899
General References
Not Available
Human Metabolome Database
HMDB0003339
KEGG Compound
C00217
PubChem Compound
23327
PubChem Substance
46508281
ChemSpider
21814
BindingDB
26431
RxNav
1428878
ChEBI
15966
ChEMBL
CHEMBL76232
ZINC
ZINC000000895124
Guide to Pharmacology
GtP Drug Page
PDBe Ligand
DGL
PDB Entries
148l / 1ay3 / 1c4b / 1cvq / 1cw8 / 1cwz / 1czq / 1d0k / 1eva / 1evb
show 247 more
MSDS
Download (47.3 KB)

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)201 °CPhysProp
water solubility8880 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
Predicted Properties
PropertyValueSource
Water Solubility80.6 mg/mLALOGPS
logP-3.5ALOGPS
logP-3.2Chemaxon
logS-0.26ALOGPS
pKa (Strongest Acidic)1.88Chemaxon
pKa (Strongest Basic)9.54Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area100.62 Å2Chemaxon
Rotatable Bond Count4Chemaxon
Refractivity31.29 m3·mol-1Chemaxon
Polarizability13.19 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption-0.6118
Blood Brain Barrier+0.6942
Caco-2 permeable-0.8531
P-glycoprotein substrateNon-substrate0.7026
P-glycoprotein inhibitor INon-inhibitor0.9815
P-glycoprotein inhibitor IINon-inhibitor0.9899
Renal organic cation transporterNon-inhibitor0.9437
CYP450 2C9 substrateNon-substrate0.8516
CYP450 2D6 substrateNon-substrate0.8559
CYP450 3A4 substrateNon-substrate0.755
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9724
CYP450 2D6 inhibitorNon-inhibitor0.9583
CYP450 2C19 inhibitorNon-inhibitor0.9729
CYP450 3A4 inhibitorNon-inhibitor0.9306
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9966
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9232
BiodegradationReady biodegradable0.9051
Rat acute toxicity0.7222 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9761
hERG inhibition (predictor II)Non-inhibitor0.9798
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0k9x-9300000000-a43e0122a45b9abf09d6
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0002-0900000000-ad4a2989e599a67182c0
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0udi-0900000000-c449cfd2231fe941d44f
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0udi-1900000000-f71458032a132069f94f
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0udi-7900000000-810570c8cfcea8da64f5
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0006-9000000000-d5167570d11d77fd541e
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0002-0900000000-c7d42b011a328bb7991d
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001i-9300000000-9fd882f84339f600b5eb
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001i-9000000000-407a30a35de9c1cceb3a
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001i-9000000000-8610ea89d52ef116caf5
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0a4i-9000000000-331b7ed6ea33880c306e
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0019-9500000000-91dbdb6677145969ec82
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udi-0900000000-fd801745085b88166c67
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udr-8900000000-3095c8c8cfff8fe0ef75
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-001i-9000000000-a1dc17fc4b005f6214ae
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9000000000-c96b3a7a2e5890612ec6
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-9000000000-f924397855763f4b4c4c
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-130.0213365
predicted
DarkChem Lite v0.1.0
[M-H]-130.1826365
predicted
DarkChem Lite v0.1.0
[M-H]-129.9854365
predicted
DarkChem Lite v0.1.0
[M-H]-122.95009
predicted
DeepCCS 1.0 (2019)
[M+H]+131.3155365
predicted
DarkChem Lite v0.1.0
[M+H]+130.7872365
predicted
DarkChem Lite v0.1.0
[M+H]+130.0377365
predicted
DarkChem Lite v0.1.0
[M+H]+126.81465
predicted
DeepCCS 1.0 (2019)
[M+Na]+130.6603365
predicted
DarkChem Lite v0.1.0
[M+Na]+130.0442365
predicted
DarkChem Lite v0.1.0
[M+Na]+129.4216365
predicted
DarkChem Lite v0.1.0
[M+Na]+135.92477
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Geobacillus stearothermophilus
Pharmacological action
Unknown
General Function
Extracellular zinc metalloprotease.
Specific Function
metal ion binding
Gene Name
nprS
Uniprot ID
P43133
Uniprot Name
Thermolysin
Molecular Weight
60616.22 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]

Drug created at June 13, 2005 13:24 / Updated at July 02, 2020 13:18